drugset / Trial / NCT00174577
Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant
Phase 3
Unknown
84 enrolled
Rhode Island Hospital
Emory University · collabJanssen Pharmaceutica N.V., Belgium · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety and efficacy of risperidone augmentation in patients who have failed to respond or only partially responded to an adequate trial of an antidepressant.
Timeline
- Start
- 2003-02
- Primary completion
- —
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 1 mg | — |
| Subject | Risperidone | Other / unclassified | 3 mg | — |